University of Kentucky

UKnowledge
Plant and Soil Sciences Faculty Patents

Plant and Soil Sciences

6-5-2012

Sesquiterpene Synthase Gene and Protein
Joe Chappell
University of Kentucky, chappell@uky.edu

Bryan Greenhagen

Follow this and additional works at: https://uknowledge.uky.edu/pss_patents
Part of the Plant Sciences Commons

Right click to open a feedback form in a new tab to let us know how this document benefits you.
Recommended Citation
Chappell, Joe and Greenhagen, Bryan, "Sesquiterpene Synthase Gene and Protein" (2012). Plant and Soil
Sciences Faculty Patents. 7.
https://uknowledge.uky.edu/pss_patents/7

This Patent is brought to you for free and open access by the Plant and Soil Sciences at UKnowledge. It has been
accepted for inclusion in Plant and Soil Sciences Faculty Patents by an authorized administrator of UKnowledge.
For more information, please contact UKnowledge@lsv.uky.edu.

USOO8192950B2

(12) United States Patent
Chappell et a].
(54)

SESQUITERPENE SYNTHASE GENE AND

2007/0231861 A1

10/2007

2007/0238157 A1

10/2007 Millis et al. ..

2007/0238159 A1
2007/0238160 A1

10/2007
10/2007

2007/0254354 A1

11/2007 Millis et al.

(73) Assignee: The University of Kentucky Research

Foundation, Lexington, KY (U S)
Notice:

Subject to any disclaimer, the term of this
patent is extended or adjusted under 35

2008/0178354 A1
2008/0213832 A1

Oct. 28, 2008

(65)

Prior Publication Data

US 2010/0216186 A1

Aug. 26,2010

Related US. Application Data

(60)

Continuation of application No. 10/ 899,356, ?led on
Jul. 26, 2004.

Provisional application No. 60/489,514, ?led on Jul.
24, 2003.

435/166
.. 435/252.33
.. 435/252.33

.. 435/252.33

Chappellet a1. ............ .. 800/298
Schalk et al. .............. .. 435/69.1

2008/0233622 A1

9/2008 Julien et al. ..
2/2010
5/2010
5/2010

435/148

Millis et al. ..
Chappell .... ..
Julien et a1. ..

. 435/254.2
435/166
.. 424/65

2010/0151519 A1

6/2010 Julien et a1. ..

435/69.1

2010/0151555 A1

6/2010

EP
EP
WO
WO
WO
WO
WO
WO
WO
WO
WO

Julien et a1. ................. .. 435/193

0 036 776
0 073 657
97/38703
99/37139
00/17327
02/072758
03/025193
2004031376 A2
2005/021705
2006/079020
2010/019696

5/1988
12/1990
10/1997
7/1999
3/2000
9/2002
3/2003
4/2004
3/2005
7/2006
2/2010

OTHER PUBLICATIONS
Drawert, F. et al. Plant Cell Reports (1984) vol. 3: pp. 37-40.*
Altschul, S., “Amino acid substitution matrices from an information

theoretic perspective,” J. M01. Biol. 219(3):555-565 (1991).
ATCC Accession No. CCL 10TM, Depositor: Macpherson, I.,,
Retrieved

(51) Int. Cl.
C12P 1/00
C12P 7/00
C12P 7/40

Millis et al. ..
Millis et al. ..

FOREIGN PATENT DOCUMENTS

(21) App1.No.: 12/259,497
(22) Filed:

7/2008
9/2008

Millis et al. ................ .. 435/69.1

2010/0035329 A1
2010/0120110 A1
2010/0129306 A1

U.S.C. 154(b) by 475 days.

(63)

Jun. 5, 2012

PROTEIN

(75) Inventors: Joseph Chappell, Lexington, KY (US);
Bryan Greenhagen, Belmont, MA (US)

(*)

US 8,192,950 B2

(10) Patent N0.:
(45) Date of Patent:

from

the

Internet : <URL : atcc .org/ATC

CAdvancedCatalogSearch/ProductDetails/tabid/452/Default.aspx,

(2006.01)
(2006.01)
(2006.01)

[accessed Feb. 27, 2011; 3 pages].
ATCC Accession No. CCL 70, derived from CV-l cell line, Deposi
tor: Jensen, F, Retrieved from the Internet:<URL:atcc.org/ATC

(52)

US. Cl. ....................................... .. 435/41; 435/71.1

(58)

Field of Classi?cation Search .................. .. 435/41,

435/71.1

See application ?le for complete search history.

CAdvancedCatalogSearch/ProductDetails/tabid/452/Default.aspx,
[accessed Feb. 25, 2011; 4 pages].
ATCC Accession No. CCL 163, Depositor: Aaronson, S., Retrieved
from the Internet:<URL:atcc.org/ATCCAdvancedCatalogSearch/

ProductDetails/tabid/452/Defaultaspx, [accessed Feb. 25, 2011; 3

pages].
(56)

References Cited

ATCC Accession No. CRL 1651, Cell Type: SV40 transformed,
Depo sitor: Gluzman, Y., Retrieved from the Internet: <URL:atcc .org/

ATCCAdvancedCatalogSearch/ProductDetails/tabid/452/Default.

U.S. PATENT DOCUMENTS
4,693,905 A
9/1987 Japikse et a1.

aspx, [accessed Feb. 25, 2011; 4 pages].
ATCC Accession No. CRL 10478, Depositor: Immunex Corporation,

4,973,485 A
5,260,086 A

11/1990 Rich
11/1993 Downton et a1.

5,589,619 A
5,824,774 A
5,981,843 A

12/1996 Chappellet a1. ............ .. 800/205
10/1998 Chappellet a1. ............ .. 530/350
11/1999 Chappellet a1. ............ .. 800/301

6,072,045 A
6,468,772 B1

6/2000 Chappellet a1.

Retrieved

536/231

10/2002 Chappellet a1. ............ .. 435/183

6,495,193 B2

12/2002 Hiramoto et a1.

6,495,354 B2

12/2002 Chappellet a1. ............ .. 435/183

from

the

Internet : <URL : atcc .org/ATC

CAdvancedCatalogSearch/ProductDetails/tabid/452/Default.aspx,
[accessed Feb. 25, 2011; 4 pages].
ATCC Accession No. 37092, Depo sitor: Bernard, H., Retrieved from
the

Internet: <URL :atcc .org/ATCCAdvancedCatalogSearch/

ProductDetails/tabid/452/Defaultaspx, [accessed Apr. 28, 2010; 2

pages].

6,531,303 B1

3/2003 Millis et a1.

. 435/155

(Continued)

6,559,297 B2

5/2003 Chappellet al.

536/231

Primary Examiner * Russell Kallis

5/2003 Chapellet a1.

. 435/183

6,569,656 B2
6,645,762 B2
6,689,593 B2

11/2003 Chappellet a1. ............ .. 435/325
2/2004 Millis et a1. ................. .. 435/155

6,890,752 B2
7,186,891 B1

5/2005 Chappellet a1.
3/2007 Chappellet a1.

7,273,735 B2*

9/2007

7,405,057 B2

7/2008 Chappellet a1.

Schalk et a1.

.... ..

. 435/325
. 800/298
. 435/166

.. 435/69.1

7,442,785 B2

10/2008 Chappellet al.

536/236

7,622,614 B2
7,790,426 B2

11/2009 Julien et a1.
9/2010 Schalketal. ..

. 568/327
435/167

2003/0166255
2003/0185956
2003/0203090
2004/0078840

A1
A1
A1
A1

9/2003

Chappell et al. ......... .. 435/252.3

1 0/ 2003 Gradley
10/ 2003 Kotachi et al.
4/2004

Chappell et al. ............ .. 800/278

2005/0210549 A1

9/2005

Schalk et al.

2006/0218661 A1

9/2006 Chappellet al.

2007/0089198 A1

4/2007 Chappellet al. ............ .. 800/280

.... ..

. 800/287

. 800/278

(74) Attorney, Agent, 0rFirm * McKenna Long &Aldridge

LLP; Stephanie Seidman
(57)
ABSTRACT
The invention relates to sesquiterpene synthases and methods
for their production and use. Particularly, the invention pro
vides nucleic acids comprising the nucleotide sequence of
citrus valencene synthase (CVS) Which codes for at least one
CVS. The invention further provides nucleic acids compris
ing the nucleotide sequence coding for amino acid residues
forming the tier 1 and tier 2 domains of CVS. The invention
also provides for methods of making and using the nucleic
acids and amino acids of the current invention.

9 Claims, 13 Drawing Sheets

US 8,192,950 B2
Page 2
OTHER PUBLICATIONS

GenBank Accession No. ACX70155.1, “terpene synthase 1 [Citrus
sinensis],” Retrieved from the Internet:<URL:ncbi.nlm.nih.gov/pro

ATCC Accession No. 53082, Depositors: Immunex Corporation and
S.Gillis., Retrieved from the Internet:<URL:atcc.org/ATC

tein/ACX70155.1, Published on Oct. 20, 2009. [accessed Feb. 25,

CAdvancedCatalogSearch/ProductDetails/tabid/452/Default.aspx,

GenBank Accession No. AF288465, “Citrus junos terpene synthase
mRNA, complete cds,” Retrieved from the Internet:<URL:ncbi.nlm.
nih.gov/nucore/9864188, Published on Aug. 22, 2000. [accessed Feb.

[Apr. 28, 2010; 2 pages].
Back et al., “Expression of a plant sesquiterpene cyclase gene in
Escherichia coli,” Arch. Biochem. Biophys. 315:527-532 (1994).
Back, K. and J. Chappell, “Cloning and bacterial expression of a
sesquiterpene cyclase from Hyoscyamus muticus and its molecular
comparison to related terpene cyclases,” J. Biol. Chem. 270:7375
7381 (1995).
Back, K. and J. Chappell, “Identifying functional domains within
terpene cyclases using a domain-swapping strategy,” Proc. Natl.

2011] [2 pages].

25,2011] [2 pages].
GenBank Accession No. AF411120, “Citrus x paradisi putative

terpene synthase mRNA, complete cds,” Retrieved from the
Internet:<URL:ncbi.nlm.nih.gov/nucore/AF411120, Published on

Apr. 2, 2002. [accessed Feb. 25, 2011] [2 pages].
Gluzman, Y., “SV40-transformed simian cells support the replication

ofearly SV40 mutants,” Cell 23(1):175-182 (1981).

Acad. Sci. USA. 93:6841-6845 (1996).
Back et al., “Cloning of a sesquiterpene cyclase and its functional

Goeddel et al., “Direct expression in Escherichia coli of a DNA

expression by domain swapping strategy,” Mol. Cells 10:220-225

(1979).

(2000).

Goeddel et al., “Synthesis of human ?broblast interferon by E. coli,”
Nucleic Acids Res. 8:4057-4074 (1980).
Greenhagen, B. and J. Chappell, “Molecular scaffolds for chemical

Bauer et al., “A genetic enrichment for mutations constructed by

oligodeoxynucleotide-directed

mutagenesis,”

Gene

37:73-81

(1985).

sequence coding for human growth hormone,” Nature 281 :544-548

wizardry: learning nature’s rules for terpene cyclases,” Proc. Natl.

Beier, D. and E. Young, “Characterization of a regulatory region
upstream of the ADRZ locus of S. cerevisiae,” Nature 300:724-728

Acad. Sci. USA. 98:13479-13491 (2001).

to

Greenhagen et al., “Probing sesquiterpene hydroxylase activities in a
coupled assay with terpene synthases,” Arch. Biochem. Biophys.
409:385-394 (2003).
Greenhagen, B., “Origins of isoprenoid diversity: A study of struc

Cane, D., “Enzymatic formation of sesquiterpenes,” Chem. Rev.

ture-function relationships in sesquiterpene synthases,” Dissertation,
College of Agriculture at the University of Kentucky (2003) [163

(1982).
Calvert et al., “Germacrene A is a product of the aristolochene

synthase-mediated conversion of farnesylpyrophosphate
aristolochene,” J. Am. Chem. Soc. 124:11636-11641 (2002).

90: 1089-1 103 (1990).
Chang et al., “Phenotypic expression in E. coli of a DNA sequence
coding for mouse dihydrofolate reductase,” Nature 275:617-624

(1978).

pages].
Hess et al., “Cooperation of glycolytic enzymes,” Adv. Enzyme Reg.
7:149-167 (1969).

Chappell, J ., “Biochemistry and molecular biology of the isoprenoid
bio synthetic pathway in plants,” Annu. Rev. Plant Physiol. Plant Mol.
Biol. 46:521-547 (1995).
Chappell et al., “Is the reaction catalyzed by 3-hydroxy-3
methylglutaryl coenzyme A reductase a rate-limiting step for

Hitzeman et al., “Isolation and characterization of the yeast
3-phosphoglycerokinase gene (PGK) by an immunological screen
ing technique,” J. Biol. Chem. 255:12073-12080 (1980).
Holland, M. and J. Holland, “Isolation and identi?cation of yeast
messenger ribonucleic acids coding for enolase, glyceraldehyde-3

isoprenoid biosynthesis in plants,” Plant Physiol. 109:1337-1343

(1995).

phosphate dehydrogenase, and phosphoglycerate kinase,” Biochem.
17:4900-4907 (1978).

Chappell, J ., “The biochemistry and molecular biology of isoprenoid

Joly, A. and P. Edwards, “Effect of site-directed mutagenesis of

metabolism,” Plant Physiol. 107:1-6 (1995).

conserved aspartate and arginine residues upon farnesyl dipho sphate
synthase activity,” J. Biol. Chem. 268:26983-26989 (1993).
Kunkel, “Rapid and ef?cient site-speci?c mutagenesis without phe

Chappell, J ., “The genetics and molecular genetics of terpene and

sterol origami,” Curr. Opin. Plant Biol. 5:151-157 (2002).
Chappell, J ., “Valencene synthaseia biochemical magician and har

binger oftransgenic aromas,” Trends Plant Sci. 9(6):266-269 (2004).
Craik, C., “Use of oligonucleotides for site-speci?c mutagenesis,”
BioTechniques Jan. 12-19, 1985.
El Tamer et al., “Domain swapping of Citrus limon monoterpene

synthases: impact on enzymatic activity and product speci?city,”
Arch. Biochem. Biophys. 411:196-203 (2003).

Eyal, E., “Computer modeling of the enzymatic reaction catalyzed by
5-epi-aristolochene cyclcase,” Masters Thesis, Department of Plant
Sciences, Weizmann Institute of Science, Rehovot, Israel (Jan. 2001)
[44 pages].

notypic selection,” Proc. Natl. Acad. Sci. USA. 82:488-492 (1985).
Kunkel et al., “Rapid and ef?cient site-speci?c mutagenesis without

phenotypic selection,” Meth. Enzymol. 154:367-382 (1987).
Laskovics, F. and C. Poulter, “Prenyltransferase: determination of the
binding mechanism and individual kinetic constants for

farnesylpyrophosphate synthetase by rapid quench and isotope par
titioning experiments,” Biochem. 20:1893-1901 (1981).
Louzada et al., “Isolation of a terpene synthase gene from mature

“Rio Red” grapefruit using differential display,” Program Schedule
and Abstracts for the 98th Annual International Conference of the

Facchini, P. and J. Chappell, “Gene family for an elicitor-induced
sesquiterpene cyclase in tobacco,” Proc. Natl. Acad. Sci. USA.

American Society for Horticultural Science, Sacramento, CA, Jul.

89:11088-11092 (1992).
Fleer et al., “High-level secretion of correctly processed recombinant
human interleukin-15in Kluyveromyces lactis,” Gene 107:285-295

Luckow, V. and M. Summers, “Trends in the development of
baculovirus expression vectors,” Nature Biotechnol. 6:47-55 (1988).
Maniatis et al., “Molecular Cloning: A Laboratory Manual,” Cold

(1991).

22-25, 2001, HortScience 36(3):440 (2001).

[Citrus x paradisi],” Retrieved from the Internet:<URL:ncbi.nlm.nih.

Spring Harbor Laboratory, p. 412 (1982).
Mathis et al., “Pre-steady-state study of recombinant sesquiterpene
cyclases,” Biochem. 36:8340-8348 (1997).

gov/protein/AAMOO426.1, Published on Apr. 2, 2002. [accessed

Newman et al., “Characterization of the TAC box, a cis-element

Feb. 28, 2011] [2 pages].

within a elicitor-inducible sesquiterpene cyclase promoter,” Plant J.

GenBank Accession No. AAQ0468.1 (AF441124i1), valencene
synthase [Citrus sinensis], Retrieved from the Internet:<URL:ncbi.

1611-12 (1998).
Newman, J. and J. Chappell, “Isoprenoid biosynthesis in plants:
carbon partitioning within the cytoplasmic pathway,” Crit. Rev.

GenBank Accession No. AAM00426.1, “putative terpene synthase

nlm.nih.gov/protein/33316389, Published on Jan.

12, 2004.

[accessed Feb. 25, 2011] [1 page].

Biochem. Mol. Biol. 34:95-106 (1999).

GenBank Accession No. ACK18099, “Sequence 4 from patent US
7442785,” Retrieved from the Internet:<URL:ncbi.nlm.nih.gov/pro
tein/ACK18099, Published on Dec. 10, 2008. [accessed Feb. 25,

Ohnuma et al., “A role of the amino acid residue located on the ?fth

position before the ?rst aspartate-rich motif of farnesyl dipho sphate

2011] [2 pages].

271:30748-30754 (1996).

sythase of determination of the ?nal product,” J. Biol. Chem.

US 8,192,950 B2
Page 3
Proctor, R. and T. Hohn, “Aristolochene synthase. Isolation, charac
terization, and bacterial expression of a sesquiterpenoid biosynthetic
gene (Ari!) from Penicillium roqueforti,” J. Biol. Chem. 268:4543
4548 (1993).
Ralston et al., “Biochemical and molecular characterization of 5-epi
aristolochene 3-hydroxylase, a putative regulatory enzyme in the
biosynthesis of sesquiterpene phytoalexins in tobacco,” Plant Inter
actions With Other Organisms. Annual Meeting of the American
Society of Plant Physiologists. Madison, WI., Jun. 27-Jul. l, 1998,
Session 47:Abstract #737 (Poster Presentation).
Ralston et al., “Cloning, heterologous expression, and fuctional char
acterization of 5-epiaristolochene-l,3-dihydroxylase from tobacco
(Nicotiana tabacum),” Arch. Biochem. Biophys. 393:222-235

(2001).
Rising et al., “Demonstration of germacrene A as an intermediate in

5-epi-aristolochene synthesis catalysis,” J. Am. Chem. Soc.
122:1861-1866 (2000).
Russell et al., “Nucleotide sequence of the yeast alcohol

dehydrogenase II gene,” J. Biol. Chem. 258:2674-2682 (1982).
Schalk, M. and R. Croteau, “A single amino acid substitution (F3631)
converts the regiochemistry of the spearmint (—)-limonene
hydroxylase from a C6- to a C3-hydroxylase,” Proc. Natl. Acad. Sci.

USA. 97:11948-11953 (2000).
Schenk et al., “Stereochemistry and deuterium isotope effects asso

ciated With the cyclization-rearrangements catalyzed by tobacco

epiaristolochene and hyoscyamus premnaspirodiene synthases, and

van den Berg et al., “Kluyveromyces as a host for heterologous gene

expression: expression and secretion of prochymosin,” Biotechnol.
8:135-139 (1990).
Walder, R. and J. Walder, “Oligodeoxynucleotide-directed
mutagenesis using the yeast transformation system,” Gene 42: 133
139 (1986).
Yin et al., “Regulation of sesquiterpene cyclase gene expressioni
characterization of an elicitor- and pathogen-inducible promoter,”

Plant Physiol. 115:437-451 (1997).
Zhao et al., “Eremophilane sesquiterpenes from capsidiol,” J. Org.
Chem. 69:7428-7435 (2004).
Allylix, “Protein engineering and chembiosynthesis to produce novel
sesquiterpenoids,” Presentation at BIO World Congress on Industrial

Biotechnology & Bioprocessing, Washington, DC. (Jun. 28, 2010).
Deguerry et al., “The diverse sesquiterpene pro?le of patchouli,
Pogostemon cablin, is correlated With a limited Number of

sesquiterpene synthases,” Arch. Biochem. Biophys. 454: 123-136

(2006).
Greenhagen et al., “Identifying and manipulating structural determi
nates linking catalytic speci?cities in terpene synthases,” Proc. Natl.
Acad. Sci. USA. 103:9826-9831 (2006).
Lee and Chappell, “Biochemical and genomic characterization of

terpene synthases in Magnolia grandi?ora,” Plant Physiol.
147:1017-1033 (2008).
O’Maille et al., “Biosynthetic potential of sesquiterpene synthases:
alternative products of tobacco S-epi-aristolochene synthase,” Arch.
Biochem. Biophys. 448:73-82 (2006).

the chimeric CH4 hybrid cyclase,” Arch. Biochem. Biophys. 448 :3 l -

Wu et a1 ., “Redirection of cytosolic or plastidic isoprenoid precursors

44 (2006).

elevates terpene production in plants,” Nat. Biotechnol. 24:l44l
1447 (2006).
Louzada et al., “Identi?cation of a gene highly expressed in juice
vesicles of mature Rio Red grapefruit using deferential display”
Citrus Center, Texas A&M (Aug. 16, 2001).
Accession No. AF4l l 120, Citrus x paradisi, WWW.ncbi.nlm.nih.gov

Sharon-Asa et al., “Citrus fruit ?avor and aroma biosynthesis: isola

tion, functional characterization, and developmental regulation of
Cstps l, a key gene in the production of the sesquiterpene aroma

compound valencene,” Plant J. 36:664-674 (2003).
Starks et al., “Structural basis for cyclic terpene biosynthesis by
tobacco 5-epi-aristolochene synthase,” Science 277:1815-1820

(1997).
Studier, F. and B. Moffatt, “Use of bacteriophage T7 RNA

polymerase to direct selective high-level expression of cloned genes,”
J. Mol. Biol. 189:113-130 (1986).
Thai et al., “Farnesol is utilized for isoprenoid biosynthesis in plant

cells

via

famesyl

pyrophosphate

formed

by

successive

monophosphorylation reactions,” Proc. Natl. Acad. Sci. USA.

96:13080-13085 (1999).

(2002).
Maruyama et al.. “Molecular Cloning, Functional Expression and
Characterization of (E)-Beta-Famesene Synthase from Citrus junos,”
Biol. Pharm. Bulletin (2001) 24: 1 171-1 175.

Tholl, D., “Terpene Synthases and the Regulation, Diversity and
Biological Roles of Terpene Metabolism,” Current Opinion in Plant

Biology (2006) 9:297-304.
* cited by examiner

US. Patent

Jun. 5, 2012

Sheet 1 0f 13

US 8,192,950 B2

1
A
A
A
A
A
A
A

K

»>

US. Patent

Jun. 5, 2012

Sheet 2 0f 13

US 8,192,950 B2

US. Patent

Jun. 5, 2012

Sheet 3 0f 13

US 8,192,950 B2

US. Patent

Jun. 5, 2012

Sheet 4 0f 13

US 8,192,950 B2

US. Patent

Jun. 5, 2012

Sheet 5 0f 13

US 8,192,950 B2

gliz'izg 5: H

US. Patent

Jun. 5, 2012

US 8,192,950 B2

Sheet 6 0f 13

125.

+1..V.

z

1 ),

.v .r

US. Patent

Jun. 5, 2012

Sheet 7 0f 13

US 8,192,950 B2

ABLNQCE
N{ABC3E%Y

{we
7mm
84m
Wm
4mm
M30 ,

mm

mm
14m

FIG, 8

US. Patent

Jun. 5, 2012

Sheet 8 0f 13

US 8,192,950 B2

WWW 3%
Ii

m

US. Patent

Jun. 5, 2012

$11RT“

fig» Z2

US 8,192,950 B2

Sheet 9 0f 13

5

US. Patent

Jun. 5, 2012

Sheet 10 0f 13

US 8,192,950 B2

US. Patent

Jun. 5, 2012

Sheet 11 0113

US 8,192,950 B2

US. Patent

Jun. 5, 2012

Sheet 12 0113

US 8,192,950 B2

US. Patent

Jun. 5, 2012

Sheet 13 0f 13

US 8,192,950 B2

US 8,192,950 B2
1

2

SESQUITERPENE SYNTHASE GENE AND

and aroma compounds; (b) separating the solvent gas and
dissolved compounds from the remaining undissolved com

PROTEIN

pounds; and (c) separating the dissolved compounds from the
RELATED APPLICATION

solvent gas.
Rich, in US. Pat. No. 4,973,485, discloses a method of

Bene?t of priority under 3 5 US .C. 119(e) is claimed herein
to US. Provisional Application No. 60/489,514, ?led Jul. 24,
2003, and bene?t of priority under 35 U.S.C. 120 is claimed
herein to US. Utility application Ser. No. 10/899,356, ?led

producing aqueous orange stripper essences and orange strip
per oils with high ratios of valencene to the less desirable
orange ?avor compounds. This procedure involves the fol
lowing steps: (a) heating an orange fed juice stream to a
temperature of 37.7° C. to 71 ° C.; (b) stripping the heated feed

on Jul. 26, 2006, now US. Pat. No. 7,442,758, issued Oct. 28,
2008. The disclosures of the above referenced applications

juice with steam at a steam: soluble solids ratio of 0.3 to 1.5, at
a temperature of 37.7° C. to 71° C. and at a stripping column

are incorporated by reference in their entirety herein.

pressure of less than 9 inches of Hg, absolute; (c) condensing
FIELD OF THE INVENTION

the stripped volatiles at a temperature of 406° C. to —196° C.;
(d) centrifuging the condensate in a continuous stacked disk

This invention relates generally to the ?eld of production of
valencene and nootkatone, and more particularly relates to
the discovery of a valencene synthase gene and related pro

hermetic centrifuge to produce two clear phases; and (e)
removing the aqueous orange stripper essence phase.

tein, which provides a pathway for generating highly pure

cess for making an aseptic citrus sensible pulp/juice slurry by

valencene which can be converted into the ?avorant, nootka

In US. Pat. No. 5,260,086 Downton et al. describe a pro
20

extracting and removing juice from citrus juice containing
sensible pulp. After this process is complete, ?avorants, such

tone.

as valencene are added to make up for those that are lost

BACKGROUND

Terpenes are a diverse family of compounds with carbon

during this extraction process.
25

Hiramoto et al., in US. Pat. No. 6,495,193 prepares a citrus
?avor from a low-boiling part of a cold pressed oil by a

skeletons composed of ?ve-carbon isoprene units. Approxi
mately 20,000 different terpenes and terpenoids (compounds

hydrate alcohol solvent extraction. To maintain the stability
of the ?avor, a stabiliZing coumarin analogue component is

of terpene origin whose carbon skeleton has been altered or

added.
In a US Patent Application, publication number US

rearranged) have been identi?ed to date, representing only a
small fraction of the estimated natural variation. Terpenes are

30

commonly isolated from the essential oils of plants. Essential
oils often have pleasant tastes or aromas, and they are widely
used as ?avorings, deodorants, and medicines.
Sesquiterpenes are terpenes with 15 carbon atoms (three

isoprene units). The plant kingdom contains the highest diver

35

sity of sesquiterpenes. Often they play a role in defense of the
plants against pathogens, insects and herbivores and for
attraction of pollinating insects.

Valencene (1 ,2,3,5,6,7,8,8a-octahydro-7-isopropenyl-1,
8a-dimethyl-naphthalene) and nootkatone (4,4a,5,6,7,8

through the membrane and into the hydrophobic phase.

40

hexahydro-6-isopropenyl-4,4-a-dimethyl-2(3H)-naphthale
from cyclization of the ubiquitous pyrophosphate intermedi
ate famesyl diphosphate. Nootkatone is formed by the oxida

and grapefruit. Because of its excellent organoleptic qualities
and in particular its typical grapefruit taste, nootkatone is a
widely used ingredient in perfumery and the ?avor industry.

Kotachi et al., in US Patent Application, publication num
ber 20030203090, teaches of a process for preparing orange
oil useful as fragrance or ?avor material, by mixing raw
material oil containing valencene with a high-boiling solvent

having a boiling point exceeding 240° C. under normal pres
sure, to give a mixture, and fractionally distilling the mixture

none) are just two examples of sesquiterpenes that are derived
tion of valencene.
Valencene and nootkatone are compounds of natural ori
gin, and are natural constituents of citrus oils, such as orange

20030185956, Gradley claims a separation method for
extracting desired sesquiterpene aroma compounds, such as
valencene and nootkatone, from an aqueous phase by sepa
rating the aqueous mixture from a water-immiscible hydro
phobic phase by means of a hydrophilic membrane and allow
ing the desired components to move out off the aqueous phase

45

obtained.
Nootkatone is a high demand, high value ?avorant added to
many of the commercial soft drinks sold worldwide. Cur

rently, the practice of extracting nootkatone from citrus pulp
and rind is considered an expensive and somewhat unreliable
process. Nootkatone can be synthesized by the oxidation of
valencene. The valencene starting material is expensive and is
50

easily degraded during evaporative heat concentration pro

Alternatively, nootkatone may be used as an insecticide.

cesses typically used to remove the bulk of water from the

Valencene, the starting material for the generation of nootka

feed juice. Thus, current methods to purify valencene from
citrus fruits are costly, di?icult, and are limited by what the

tone (either biologically or chemically), is also used as a

?avorant and fragrance.
Several methods to purify sesquiterpenes, such as valen
cene and nootkatone, from citrus fruits or to maintain high
levels of these sesquiterpenes in citrus fruit extracts have been
described in the prior art. These methods are described below.
Japikse et al., in US. Pat. No. 4,693,905, claimed a method
of extracting concentrated orange ?avor and aroma compo
sitions from natural orange essence oil by using a dense

fruit can deliver. Moreover, such methods are vulnerable to
55

interruptions in the supply of citrus fruits, which is dependent
on the weather. A frost or hailstorm in a major citrus fruit

growing region such as Florida can interrupt the supply. Fur
thermore, methods to produce nootkatone that consume
valencene are quite costly, and thus not commercially desir
60

able. Therefore, there is a need for an alternative means for

preparing valencene and nootkatone.

solvent gas. Their procedure entailed (a) contacting natural
SUMMARY OF THE INVENTION

orange essence oil with a solvent gas having a temperature

between its critical temperature and 100° C., and having a
reduced pressure between about 0.56 and about 1.31 (where
reduced pressure is de?ned as the extraction pressure of the

solvent gas divided by its critical pressure), to extract ?avor
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In one embodiment, the invention relates to isolated

nucleic acids that encode a sesquiterpene synthase. The
invention provides an isolated nucleic acid selected from: (a)

US 8,192,950 B2
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a nucleic acid comprising the nucleotide sequence substan
tially as set out in SEQ ID NO: 1; (b) a nucleic acid encoding

said nucleic acid is a sesquiterpene synthase. The host may be

chosen from, for example, plants, microorganisms, bacterial
cells, yeast cells, plant cells, and animal cells.

the polypeptide substantially set out in SEQ ID NO: 4; and (c)
a nucleic acid that hybridizes to the nucleic acid of (a) or (b)

In another embodiment the invention provides a method of

under low stringency conditions, wherein the polypeptide

making at least one terpenoid comprising:
1) contacting at least one acyclic pyrophosphate terpene

encoded by said nucleic acid is a sesquiterpene synthase.
Other embodiments include: a polypeptide encoded by a
nucleic acid of the invention; a host cell comprising a nucleic
acid of the invention; a non-human organism modi?ed to
harbor a nucleic acid of the invention; and methods of pro

precursor with at least one polypeptide encoded by a
nucleic acid of the current invention. In one embodi
ment, the nucleic acid is chosen from (a) a nucleic acid
comprising the nucleotide sequence substantially as set
out in SEQ ID NO.: 1, SEQ ID NO.: 5 or SEQ ID NO.:

ducing a polypeptide comprising culturing host cells of the
invention.
In another embodiment, the invention provides an isolated

6; (b) a nucleic acid encoding the polypeptide substan
tially set out in SEQ ID NO: 4, SEQ ID NO.: 7 or SEQ
ID NO.: 8; and (c) a nucleic acid that hybridizes to the
nucleic acid of (a) or (b) under low stringency condi

polypeptide comprising an amino acid sequence substantially
as set out in SEQ ID NO: 4.
In a further embodiment, the invention provides a vector
comprising at least one nucleic acid chosen from (a) a nucleic

acid comprising the nucleotide sequence substantially as set
out in SEQ ID NO: 1; (b) a nucleic acid encoding the polypep
tide substantially set out in SEQ ID NO: 4; and (c) a nucleic
acid that hybridizes to the nucleic acid of (a) or (b) under low

tions, wherein the polypeptide encoded by said nucleic
acid is a sesquiterpene synthase,
2) isolating at least one terpenoid produced in 1).
In one embodiment, the at least one terpenoid is chosen
20

In a further embodiment, the at least one acyclic pyrophos

stringency conditions, wherein the polypeptide encoded by
said nucleic acid is a sesquiterpene synthase. Other embodi
ments include, methods of making a recombinant host cell
comprising introducing a vector of the invention into a host
cell.
In a further embodiment, the invention relates to isolated
nucleic acids that encode a sesquiterpene synthase. The
invention provides an isolated nucleic acid selected from: (a)
a nucleic acid comprising the nucleotide sequence substan
tially as set out in SEQ ID NO: 5 or SEQ ID NO.: 6; (b) a

phate terpene precursor is famesyl-diphosphate (FPP). The
sesquiterpene produced by the methods of the invention
include, but are not limited to, valencene, valencene deriva
25

BRIEF DESCRIPTION OF THE DRAWINGS
30

35

nucleic acid is a sesquiterpene synthase. Other embodiments
include: a polypeptide encoded by a nucleic acid of the inven

FIG. 2 illustrates a mechanism for the enzyme catalyzed

40

Two additional chiral centers develop upon formation of an
internal bond between C2 and C7. This process of proton

polypeptide comprising an amino acid sequence substantially

invention into a host cell.

45

overlapping orbitals are dependent on the orientation of the

50

55

turing a host cell modi?ed to contain at least one nucleic acid
60

and de?ne, as a consequence, the ?nal chirality of the methyl
substitutions at C2 and C3. Subsequent to these rearrange
ments, a tertiary carbocation centered at C7 is formed (an
eremophilyl cation, not shown) and alternate elimination of a
proton from C6 or C8 give two subclasses of double bond
regioisomers, illustrated as layers. Known eremophilanes are
noted by their common name.

FIG. 3 illustrates a proposed pathway for the biosynthesis
of nootkatone in citrus. The scheme suggests at least two

steps, the ?rst step is catalyzed by the sesquiterpene synthase

acid encoding the polypeptide substantially set out in SEQ ID

stringency conditions, wherein the polypeptide encoded by

orientations of the C2 p-orbitals are given on the vertical axis
of the diagram and those for C7 depicted on the horizontal
axis. These orientations direct the stereochemistry of the

ensuing methyl migrations and hydride shifts (not illustrated)

making at least one sesquiterpene synthase comprising cul

NO: 4, SEQ ID NO.: 7 or SEQ ID NO.: 8; and (c) a nucleic
acid that hybridizes to the nucleic acid of (a) or (b) under low

initiated, internal cyclization (illustrated as transition states)
requires that the p-orbitals of sp2 hybridized C2 and C7 face
and align with each other. The 4 possible combinations of
respective p-orbitals either above or below the plane of the
eudesmalyl carbocation intermediate. The possible re and si

In one embodiment, the invention provides a method of

sequence under conditions conducive to the production of
said at least one sesquiterpene synthase. In one embodiment,
the at least one nucleic acid is chosen from (a) a nucleic acid
comprising the nucleotide sequence substantially as set out in
SEQ ID NO: 1, SEQ ID NO.: 5 or SEQ ID NO.: 6; (b) a nucleic

tion of the initial carbocation, a chiral center arises from the
?rst attack on either the si or re face of sp2 hybridized C10

yielding either (10R)-germacrene A or (10S)-germacrene A.

In another embodiment, the invention provides an isolated

SEQ ID NO: 5 or SEQ ID NO.: 6; (b) a nucleic acid encoding
the polypeptide substantially set out in SEQ ID NO: 7 or SEQ
ID NO.: 8; and (c) a nucleic acid that hybridizes to the nucleic
acid of (a) or (b) under low stringency conditions, wherein the
polypeptide encoded by said nucleic acid is a sesquiterpene
synthase. Other embodiments include, methods of making a
recombinant host cell comprising introducing a vector of the

(CVS), respectively.
development of regio- and enantio-speci?city in eremo
philanes. Upon loss of the diphosphate from C1 and genera

tion; a host cell comprising a nucleic acid of the invention; a
non-human organism modi?ed to harbor a nucleic acid of the

as set out in SEQ ID NO: 7 or SEQ ID NO.: 8.
In a further embodiment, the invention provides a vector
comprising nucleic acid chosen from (a) a nucleic acid com
prising the nucleotide sequence substantially as set out in

FIG. 1 shows the conversion of FPP to the sesquiterpene

reaction products 5-epi-aristolochene, premnaspirodiene and
valencene catalyzed by Nicotiana tabacum epi-aristolochene
synthase (TEAS), Hyoscyamus mulicus premnaspirodiene
synthase (HPS), and Citrus paradisi valencene synthase

SEQ ID NO: 7 or SEQ ID NO.: 8; and (c) a nucleic acid that
hybridizes to the nucleic acid of (a) or (b) under low strin

invention; and methods of producing a polypeptide compris
ing culturing host cells of the invention.

tives, valencene fragments, and compounds having the citrus
valencene carbon skeleton.

nucleic acid encoding the polypeptide substantially set out in
gency conditions, wherein the polypeptide encoded by said

from the group consisting of sesquiterpene.
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of the current invention, denoted as “1” in the ?gure, which
leads to the production of valencene and the second step

consisting of a regio-speci?c hydroxylation, followed by oxi
dation. The second step could be catalyzed by a single mul

US 8,l92,950 B2
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tifunctional hydroxylase or could involve sequential enzyme

FIG. 1411 shows the absolute amino acid sequence from
SEQ ID NO.: 4 corresponding to the Tier 1 amino acid resi
dues. FIG. 14b shows the comparative amino acid sequence

mediated reactions, and which are denoted as “2” in the

?gure.

of the Tier 1 amino acid residues (SEQ ID NO.: 7)

FIG. 4 illustrates a sequence alignment of amino acids

FIG. 1511 shows the absolute amino acid sequence from
SEQ ID NO.: 4 corresponding to Tier 2 amino acid residues.
FIG. 15b shows the comparative amino acid sequence of the
Tier 2 amino acid residues (SEQ ID NO.: 8).
FIG. 16 is a sequence alignment of the amino acid
sequence of TEAS active site compared to the amino acid
sequence of the CVS active site. The alignment maximizes
residue similarities and introduce gaps where necessary.
Absolute amino acid numbering is shown for CVS, thus
amino acid numbering from SEQ ID NO.: 4 is shown for

lining the active site (lst tier) and those within 3 A of the
active site residues (2nd tier) of TEAS with the corresponding
positions of CVS. For uniformity, the TEAS amino acids
numbering was used, and thus the corresponding CVS amino
acids renumbereditermed comparative numbering. The 1st
tier residues lie within 3 A of a substrate analog co-crystal
lized within the TEAS enzyme and includes residues making
up the J/ K loop which clamps down over the active site upon

substrate binding. The corresponding residues within CVS

(valencene synthase) were initially identi?ed by primary

CVS.
FIG. 17 is a chart showing the TEAS Tier 1 and Tier 2
amino acid residues in column 1; the CVS Tier 1 and Tier 2

sequence alignment, then visual inspection of the relevant
CVS sequences overlaid on the TEAS 3-dimensional struc
ture. Residues different from TEAS are highlighted.

FIG. 5 shows SEQ ID NO.: 1, which is the DNA sequence
for the citrus valencene synthase gene from Citrus paradis
isolated in the current invention.
FIG. 6 shows SEQ ID NO.: 4, which is the protein sequence

for the citrus valencene synthase from Citrus paradisi.
FIG. 7 illustrates reaction product analysis of citrus valen
cene synthase (CVS) incubated at pH 7.5. Lysate of E. coli

amino acid residues with absolute numbering in column 2;
and the CVS Tier 1 and Tier 2 amino acid residues with
20

DETAILED DESCRIPTION OF THE INVENTION

Abbreviations and Terms
25

expressing the CVS cDNA was incubated with FIT at pH 7.5

In accordance with the present invention and as used
herein, the following terms and abbreviations are de?ned with

and total pentane extractable products evaluated by GC-MS
(upper panel). The mass spectrum of the reaction product
corresponding to peakA (middle panel) is compared to that of
authentic valencene in the lower panel. The mass spectrum of
peak B is identical to that for beta-elemene, the thermal

the following meanings, unless explicitly stated otherwise.
These explanations are intended to be exemplary only. They
30 are not intended to limit the terms as they are described or

referred to throughout the speci?cation. Rather, these expla

induced rearrangement product of germacrene A.
FIG. 8 illustrates a mass spectrum for the peak with a

retention time of 7.38 minutes from FIG. 7 (top) compared to

the spectra for beta-elemene published by the NIST library

35

nations are meant to include any additional aspects and/or
examples of the terms as described and claimed herein.
The following abbreviations are used herein:
As used herein, a “derivative” is any compound obtained

from a known or hypothetical compound and containing
essential elements of the parent substance.
The phrase “substantially identical” means that a relevant

(bottom).
FIG. 9 illustrates mass spectrum for the peak with a reten

tion time of 8.89 in FIG. 7 (top) compared to that for valen
cene purchased from Fluka Chemical Company (bottom).
FIG. 10 illustrates that the reaction product speci?city of

comparative numbering in column 3.

sequence is at least 70%, 75%, 80%, 85%, 90%, 92%, 95%
40

citrus valencene synthase (CVS) is pH dependent. Partially
puri?ed synthase isolated from E. coli expressing the CVS

96%, 97%, 98%, or 99% identical to a given sequence. By
way of example, such sequences may be allelic variants,
sequences derived from various species, or they may be

cDNA was incubated with FPP at the indicated pH values and

derived from the given sequence by truncation, deletion,

ethylacetate extracts were examined directly by GC-MS.
Absolute values for valencene (solid symbols) and germa
crene A (measured as the thermally rearranged product [3-el

amino acid substitution or addition. Percent identity between
45

two sequences is determined by standard alignment algo
rithms such as ClustalX when the two sequences are in best

emene) (open symbols) are reported and represent greater

alignment according to the alignment algorithm.

than 95% of the total reaction products at all pHs.
FIG. 11 is a sequence alignment of amino acids lining the

under certain conditions is intended to describe conditions for

active site (1 st tier) of TEAS with the corresponding positions

As used herein, the term “hybridization” or “hybridizes”
50

of HPS and CVS. The 1st tier residues lie within 3 A of a

substrate analog co-crystallized within the TEAS enzyme and
includes residues making up the J/ K loop which clamps down
over the active site upon substrate binding. The correspond
ing residues within the other terpene synthases were initially

hybridization and washes under which nucleotide sequences
that are signi?cantly identical or homologous to each other
remain bound to each other. Appropriate hybridization con
ditions can be selected by those skilled in the art with minimal

55

experimentation as exempli?ed in Ausubel, F. A., et al., eds.,
Current Protocols in Molecular Biology Vol. 2, John Wiley

identi?ed by primary sequence alignment, then visual inspec

and Sons, Inc., New York (1995). Additionally, stringency

tion of the relevant sequences overlaid on the TEAS 3 -dimen
sional structure. Residues in CVS differing from TEAS are

conditions are described in Sambrook et al. Molecular Clon

highlighted.

Laboratory Press, New York (1989). Variations on the condi
tions for low, moderate, and high stringency are well known

FIG. 12 shows SEQ ID NO.: 5, which is the DNA sequence
from SEQ ID NO.: 1 corresponding to the amino acids form

ing: A Laboratory Manual, 2nd ed., Cold Spring Harbor
60

in the art and may be used with the current invention.
The terms “nucleic acid” or “nucleic acid molecule” refer
to a deoxyribonucleotide or ribonucleotide polymer in either

ing Tier 1. Comparative numbering from Tier 1 amino acid
residues is also shown (SEQ ID NO.: 7).
FIG. 13 shows SEQ ID NO.: 6, which is the DNA sequence
from SEQ ID NO.: 1 corresponding to the amino acids form

ing Tier 2. Comparative numbering from Tier 2 amino acid
residues is also shown (SEQ ID NO.: 8).
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single- or double-stranded form, and unless otherwise lim
ited, would encompass known analogs of natural nucleotides
that can function in a similar manner as naturally occurring

nucleotides. A “nucleotide sequence” also refers to a poly

US 8,192,950 B2
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nucleotide molecule or oligonucleotide molecule in the form

acid sequences of the invention. Thus, in one embodiment, a
polypeptide within the scope of the invention is de?ned as an
amino acid sequence comprising a linear or 3-dimensional

of a separate fragment or as a component of a larger nucleic
acid. The nucleotide sequence or molecule may also be
referred to as a “nucleotide probe.” Some of the nucleic acid
molecules of the invention are derived from DNA or RNA
isolated at least once in substantially pure form and in a

epitope shared with any peptide encoded by the nucleic acid
sequences of the invention. Alternatively, a polypeptide
within the scope of the invention is recognized by an antibody

quantity or concentration enabling identi?cation, manipula

that speci?cally recognizes any peptide encoded by the

tion, and recovery of its component nucleotide sequence by
standard biochemical methods. Examples of such methods,
including methods for PCR protocols that may be used

nucleic acid sequences of the invention. Antibodies are

de?ned to be speci?cally binding if they bind polypeptides of
the invention with a K, of greater than or equal to about 107
M“, such as greater than or equal to 108 M‘1 . As used herein,
the term “isolated,” in reference to polypeptides or proteins,
means that the polypeptide or protein is substantially

herein, are disclosed in Sambrook et al. Molecular Cloning: A

Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory
Press, New York (1989), Ausubel, F. A., et al., eds., Current
Protocols in Molecular Biology, John Wiley and Sons, lnc.,
NewYork (1987), and Innis, M., et al. (Eds) PCR Protocols:

removed from polypeptides, proteins, nucleic acids, or other

A Guide to Methods and Applications, Academic Press, San
Diego, Calif. (1990). Reference to a nucleic acid molecule
also includes its complement as determined by the standard

macromolecules with which it, or its analogues, occurs in
nature. Although the term “isolated” is not intended to require

Watson-Crick base-pairing rules, with uracil (U) in RNA

about 75% pure, more typically at least about 90% pure,
preferably at least about 95% pure, and more preferably at
least about 99% pure.

replacing thymine (T) in DNA, unless the complement is
speci?cally excluded.

a speci?c degree of purity, typically, the protein will be at least
20

As described herein, the nucleic acid molecules of the
invention include DNA in both single-stranded and double

A polypeptide “variant” as referred to herein means a

polypeptide substantially homologous to a native polypep

stranded form, as well as the DNA or RNA complement

thereof. DNA includes, for example, DNA, genomic DNA,
chemically synthesized DNA, DNA ampli?ed by PCR, and
combinations thereof. Genomic DNA, including translated,
non-translated and control regions, may be isolated by con
ventional techniques, e. g., using any one of the cDNAs of the
invention, or suitable fragments thereof, as a probe, to iden
tify a piece of genomic DNA which can then be cloned using
methods commonly known in the art.
Polypeptides encoded by the nucleic acids of the invention
are encompassed by the invention. As used herein, reference
to a nucleic acid “encoding” a protein or polypeptide encom

25

because of one or more deletions, insertions or substitutions.

Variants can comprise conservatively substituted sequences,
meaning that a given amino acid residue is replaced by a
residue having similar physiochemical characteristics. See
30
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assumption that the introns included have appropriate splice
donor and acceptor sites that will ensure that the introns are
40

or a peptide without altering either the con?rmation or the

function of the protein or peptide. Such changes include

substituting any of isoleucine (I), valine (V), and leucine (L)
for any other of these amino acids; aspartic acid (D) for
glutamic acid (E) and vice versa; glutamine (Q) for aspar
agine (N) and vice versa; and serine (S) for threonine (T) and
vice versa.

The above-mentioned substitutions are not the only amino
acid substitutions that can be considered “conservative.”
Other substitutions can also be considered conservative,

of the genetic code wherein more than one codon can encode
the same amino acid, multiple DNA sequences can code for
the same polypeptide. Such variant DNA sequences can result

from genetic drift or arti?cial manipulation (e.g., occurring

Zubay, Biochemistry, Addison-Wesley Pub. Co., (1983). It is
a well-established principle of protein and peptide chemistry
that certain amino acids substitutions, entitled “conservative”
amino acid substitutions, can frequently be made in a protein

passes not only cDNAs and other intronless nucleic acids, but
also DNAs, such as genomic DNA, with introns, on the

spliced out of the corresponding transcript when the tran
script is processed in a eukaryotic cell. Due to the degeneracy

tide, but which has an amino acid sequence different from that
encoded by any of the nucleic acid sequences of the invention

45

depending on the environment of the particular amino acid.

during PCR ampli?cation or as the product of deliberate
mutagenesis of a native sequence). Deliberate mutagenesis of

For example, glycine (G) and alanine (A) can frequently be

a native sequence can be carried out using numerous tech

(M), which is relatively hydrophobic, can frequently be inter
changed with leucine and isoleucine, and sometimes with

niques well known in the art. For example, oligonucleotide
directed site-speci?c mutagenesis procedures can be

interchangeable, as can be alanine and valine (V). Methionine

50

valine. Lysine (K) and arginine (R) are frequently inter

employed, particularly where it is desired to mutate a gene
such that predetermined restriction nucleotides or codons are

changeable in locations in which the signi?cant feature of the
amino acid residue is its charge and the differing pK’ s of these

altered by substitution, deletion or insertion. Exemplary
methods of making such alterations are disclosed by Walder

two amino acid residues are not signi?cant. Still other

changes can be considered “conservative” in particular envi

et al. (Gene 42:133, 1986); Bauer et al. (Gene 37:73, 1985);
Craik (BioTechniques, Jan. 12-19, 1985); Smith et al. (Ge
netic Engineering: Principles and Methods, Plenum Press,
1981); Kunkel (Proc. Natl. Acad. Sci. USA 82:488, 1985);
Kunkel et al. (Methods in Enzymol. 154:367, 1987). The

55 ronments.

present invention thus encompasses any nucleic acid capable
of encoding a protein of the current invention.
The current invention provides for isolated polypeptides.

60

The effects of such substitutions can be calculated using
substitution score matrices such PAM120, PAM-200, and
PAM-250 as discussed in Altschul, (J. Mol. Biol. 219:55565

characteristics, are well known.

Naturally-occurring peptide variants are also encompassed
by the invention. Examples of such variants are proteins that

As used herein, the term “polypeptides” refers to a genus of

polypeptide or peptide fragments that encompass the amino
acid sequences identi?ed herein, as well as smaller frag
ments. Alternatively, a polypeptide may be de?ned in terms of

its antigenic relatedness to any peptide encoded by the nucleic

(1991)). Other such conservative substitutions, for example,
substitutions of entire regions having similar hydrophobicity

result from alternate mRNA splicing events or from pro
65

teolytic cleavage of the polypeptides described herein. Varia
tions attributable to proteolysis include, for example, differ
ences in the N- or C-termini upon expression in different

